Long Term Follow-up of Mesothelioma Patients and Their Family Members With Germline Mutations in BAP1 and Other Genes
| Status: | Recruiting |
|---|---|
| Conditions: | Lung Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 2 - 99 |
| Updated: | 3/23/2019 |
| Start Date: | March 13, 2019 |
| End Date: | July 5, 2027 |
| Contact: | Maria Agra |
| Email: | mariagracia.agra@nih.gov |
| Phone: | (240) 858-3152 |
Background:
-A gene provides instructions to the body. Mutated genes can sometimes cause cancer. Germline
mutations are those people are born with. These mutations in the BAP1 gene can cause
mesothelioma and other cancers. Researchers want to study people with germline mutations of
BAP1 and other genes known to cause cancer.
Objective:
-To learn how cancer might develop in people with certain gene mutations.
Eligibility:
-People ages 2 and older with a germline mutation in BAP1 or another gene that might cause
cancer
Design:
- Participants will be screened with:
- Medical and family history
- Saliva test
- Participants with mesothelioma will be in the NIH Group. Participants without
mesothelioma can choose to be in either the NIH Group or the Remote Group.
- Remote Group participants will have a medical and family history by phone. If they have
tumor tissue from a previous surgery, it will be tested. They will be contacted once a
year by phone.
- NIH Group participants will have a baseline visit. This can take up to 4 days. They may
have to stay in the area overnight. The visit will include:
- Physical exam
- Evaluation of tumor tissue if available
- Optional tumor biopsy
- Blood tests
- Scans: A machine will take pictures of the body.
- Photographs of skin lesions or other issues
- Skin exam
- Eye exam
- NIH Group participants will have visits once or twice a year. These will include a
physical exam, lab tests, scans, and other tests as needed.
- Participants who have a confirmed mutation will be asked to contact any relatives who
may be at risk and ask them about joining the study.
-A gene provides instructions to the body. Mutated genes can sometimes cause cancer. Germline
mutations are those people are born with. These mutations in the BAP1 gene can cause
mesothelioma and other cancers. Researchers want to study people with germline mutations of
BAP1 and other genes known to cause cancer.
Objective:
-To learn how cancer might develop in people with certain gene mutations.
Eligibility:
-People ages 2 and older with a germline mutation in BAP1 or another gene that might cause
cancer
Design:
- Participants will be screened with:
- Medical and family history
- Saliva test
- Participants with mesothelioma will be in the NIH Group. Participants without
mesothelioma can choose to be in either the NIH Group or the Remote Group.
- Remote Group participants will have a medical and family history by phone. If they have
tumor tissue from a previous surgery, it will be tested. They will be contacted once a
year by phone.
- NIH Group participants will have a baseline visit. This can take up to 4 days. They may
have to stay in the area overnight. The visit will include:
- Physical exam
- Evaluation of tumor tissue if available
- Optional tumor biopsy
- Blood tests
- Scans: A machine will take pictures of the body.
- Photographs of skin lesions or other issues
- Skin exam
- Eye exam
- NIH Group participants will have visits once or twice a year. These will include a
physical exam, lab tests, scans, and other tests as needed.
- Participants who have a confirmed mutation will be asked to contact any relatives who
may be at risk and ask them about joining the study.
Background:
- BRCA1-Associated Protein-1 (BAP1), a deubiquitinase involved in regulating DNA repair
enzymes, is believed to be a prominent mutation in malignant mesothelioma
- Germline mutations involving BAP1 have been reported in familial studies. These have
been associated with a higher likelihood of mesothelioma as well as several other
malignancies, including uveal melanoma, cutaneous melanomas, renal cell carcinoma and
cholangiocarcinoma
- BAP1 mutations, if found, have a high probability of detecting multiple malignancies in
family members.
Objectives:
-To characterize the natural and clinical history of malignant mesothelioma patients and
their family members who have germline mutations in BAP1 and other DNA repair/cancer
predisposition genes
Eligibility for Genetic Testing:
Cohort 1
-Individual with mesothelioma with deleterious germline mutations in BAP1 or another
DNA-repair/cancer predisposition gene(s) (previous testing may have been research or
clinical)
OR
- Individual with a diagnosis of mesothelioma who is otherwise eligible for testing on
Cohort 2
- Age greater than or equal to 2 years old
Cohort 2
-Individual with a germline BAP1 mutation who does not have a history of mesothelioma
(previous testing may have been research or clinical)
OR
-Individual with no personal history of mesothelioma with:
--a first degree biological relative (living or deceased) with a history of mesothelioma
OR
--a first degree biological relative with a CLIA confirmed germline mutation in BAP1
OR
--a first degree biological relative with mesothelioma and a CLIA confirmed germline mutation
in another DNA-repair/cancer predisposition genes
OR
--a second degree biological relative with mesothelioma and a CLIA confirmed germline
mutation in BAP1
-Age greater than or equal to 16 unless participant has a first degree biological relative
with a confirmed p53 germline mutation; in such cases, will begin screening at age greater
than or equal to 2 years old.
Eligibility for Surveillance:
Cohort 1
-No additional criteria
Cohort 2
-Testing performed on study must confirm presence of germline mutation in BAP1 or another DNA
repair/cancer predisposition gene(s)
Design:
- Individuals with suspected hereditary predisposition to mesothelioma and their families
will be recruited to assess for genetic mutations, and to study the natural history of
malignancies occurring in germline BAP1 mutations as well as other mutations involved in
DNA repair.
- Screening examinations will be offered to those with germline BAP1 mutations as well as
other mutations involved in DNA repair/cancer predispositoin.
- We will determine if there is a relationship between germline mutation and disease
phenotype.
- BRCA1-Associated Protein-1 (BAP1), a deubiquitinase involved in regulating DNA repair
enzymes, is believed to be a prominent mutation in malignant mesothelioma
- Germline mutations involving BAP1 have been reported in familial studies. These have
been associated with a higher likelihood of mesothelioma as well as several other
malignancies, including uveal melanoma, cutaneous melanomas, renal cell carcinoma and
cholangiocarcinoma
- BAP1 mutations, if found, have a high probability of detecting multiple malignancies in
family members.
Objectives:
-To characterize the natural and clinical history of malignant mesothelioma patients and
their family members who have germline mutations in BAP1 and other DNA repair/cancer
predisposition genes
Eligibility for Genetic Testing:
Cohort 1
-Individual with mesothelioma with deleterious germline mutations in BAP1 or another
DNA-repair/cancer predisposition gene(s) (previous testing may have been research or
clinical)
OR
- Individual with a diagnosis of mesothelioma who is otherwise eligible for testing on
Cohort 2
- Age greater than or equal to 2 years old
Cohort 2
-Individual with a germline BAP1 mutation who does not have a history of mesothelioma
(previous testing may have been research or clinical)
OR
-Individual with no personal history of mesothelioma with:
--a first degree biological relative (living or deceased) with a history of mesothelioma
OR
--a first degree biological relative with a CLIA confirmed germline mutation in BAP1
OR
--a first degree biological relative with mesothelioma and a CLIA confirmed germline mutation
in another DNA-repair/cancer predisposition genes
OR
--a second degree biological relative with mesothelioma and a CLIA confirmed germline
mutation in BAP1
-Age greater than or equal to 16 unless participant has a first degree biological relative
with a confirmed p53 germline mutation; in such cases, will begin screening at age greater
than or equal to 2 years old.
Eligibility for Surveillance:
Cohort 1
-No additional criteria
Cohort 2
-Testing performed on study must confirm presence of germline mutation in BAP1 or another DNA
repair/cancer predisposition gene(s)
Design:
- Individuals with suspected hereditary predisposition to mesothelioma and their families
will be recruited to assess for genetic mutations, and to study the natural history of
malignancies occurring in germline BAP1 mutations as well as other mutations involved in
DNA repair.
- Screening examinations will be offered to those with germline BAP1 mutations as well as
other mutations involved in DNA repair/cancer predispositoin.
- We will determine if there is a relationship between germline mutation and disease
phenotype.
- Inclusion Criteria:
Inclusion Criteria for Genetic Testing:
Cohort 1:
- Subject with pathology confirming a diagnosis of mesothelioma.
- Subject must have a deleterious germline BAP1 mutation. Results from either research
or clinical analyses are sufficient for this criterion.
OR
-Subject with mesothelioma otherwise eligible for genetic testing in Cohort 2
OR
- Subject must have deleterious germline mutation in another DNA repair/cancer
predisposition gene(s). Results from either research or clinical analyses are
sufficient for this criterion.
- Age greater than or equal to 2 years
Cohort 2:
-Individual with a germline BAP1 mutation who does not have a history of mesothelioma
(other cancers are allowed). Results from either research or clinical analyses are
sufficient for this criterion.
OR
-Individual with no history of mesothelioma with either:
---A biological first degree relative (living or deceased) with a history of mesothelioma
OR
---A first degree biological relative with a CLIA confirmed germline mutation in BAP1
OR
---A first degree biological relative with mesothelioma and a CLIA confirmed germline
mutation in another DNA-repair/cancer predisposition gene.
OR
- A second degree biological relative with mesothelioma and a CLIA confirmed germline
mutation in BAP1)
-Age:
- Greater than or equal to 2 years for subjects with a first degree relative that has a
germline mutation in p53
- Greater than or equal to 16 years for all other eligible potential mutations
- All participants or their legally authorized representatives (LARs) must
understand and be willing to sign a written informed consent
Inclusion Criteria for Surveillance:
- Genetic testing criteria for respective cohorts must be met
- Subjects in Cohort 1 may be enrolled with positive results for germline BAP1 mutation
or another DNA repair/cancer predisposition gene(s) regardless of CLIA confirmation
- Subjects in Cohort 2 must have CLIA confirmed germline BAP1 mutation or another DNA
repair/cancer predisposition gene(s)
We found this trial at
1
site
9000 Rockville Pike
Bethesda, Maryland 20892
Bethesda, Maryland 20892
301-496-2563
Phone: 888-624-1937
National Institutes of Health Clinical Center The National Institutes of Health (NIH) Clinical Center in...
Click here to add this to my saved trials
